Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study. By creating the most complete and detailed genetic 'map' of kidney function to ...
There’s also MZE782, an oral SCL6A19 inhibitor in a phase 1 trial with healthy volunteers and plans to pursue the drug in chronic kidney disease and phenylketonuria. From these raises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results